Trending Alert: 4 HealthTech Tickers Trending Now

Names Inside If you cannot see this email properly, please click [here]( Powered by [HealthTechMovers.com]( Dear Reader, Below is a a list of 4 Healthtech Stocks that have appear to be trending by receiving buy ratings and showing positive investor sentiment, as well as news headlines. With that said, our editors are adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [Beyond AI Stocks: The Rare Element Crucial To Modern Tech]( [Read this stunning report on a potential "tech" investment strategy]( --------------------------------------------------------------- [4D Molecular Therapeutics, Inc., FDMT]( Summary: 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California. Salveen Richter analyst at Goldman Sachs reiterates coverage on [4D Molecular Therapeutics, Inc. (FDMT)](in the Health sector with a Buy rating and has set a price target of $81. [TipRanks.com]( reports that [4D Molecular Therapeutics, Inc.](currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $56.25. In addition, TradingView issued a buy rating for [FDMT]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on FDMT, please click here >>]( --------------------------------------------------------------- [Arrowhead Pharmaceuticals, Inc., ARWR]( Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California. Edward Tenthoff analyst at Piper Sandler reiterates coverage on [Arrowhead Pharmaceuticals, Inc. (ARWR)](in the Health sector with a Buy rating and has set a price target of $62. [TipRanks.com]( reports that [Arrowhead Pharmaceuticals, Inc.](currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $55.50. In addition, TradingView issued a Sell rating for [ARWR]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the complete breakdown on ARWR, please click here >>]( --------------------------------------------------------------- Sponsor [Where AI And Mining Intersect - Overlooked Connection Revealed]( the AI "arms race" continues to heat up, a new report shines a light on just how reliant modern technology is on precious metals. This report connects the dots between global superpowers, AI dominance, and an unassuming patch of Nevada desert that could change the game as we know it. [Learn how a young US company fits into the global AI race.]( --------------------------------------------------------------- [Deciphera Pharmaceuticals, Inc., DCPH]( Summary: Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform. Andrew Fein analyst at H.C. Wainwright reiterates coverage on [Deciphera Pharmaceuticals, Inc. (DCPH)](in the Health sector with a Buy rating and has set a price target of $30. [TipRanks.com]( reports that [Deciphera Pharmaceuticals, Inc.](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $23.00. In addition, TradingView issued a Sell rating for [DCPH]( over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on DCPH, please click here >>]( --------------------------------------------------------------- [Exelixis, Inc., EXEL]( Summary: Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Yaron Werber analyst at TD Cowen reiterates coverage on [Exelixis, Inc. (EXEL)](in the Health sector with a Buy rating and has set a price target of $25. [TipRanks.com]( reports that [Exelixis, Inc.](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $25.60. In addition, TradingView issued a Strong sell rating for [EXEL]( over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on EXEL, please click here >>]( --------------------------------------------------------------- Sponsor [I Couldn't Air my Biggest A.I. Prediction]( built the indicator that Wall Street uses to find winning stocks. Now he's issuing a new prediction about the A.I. market. [Learn more here.]( --------------------------------------------------------------- --------------------------------------------------------------- Sponsor [Best way to buy gold today (not what you'd think)]( so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion. [Full details here.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [TipRanks.com]( tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [HealthTechMovers.com]( --------------------------------------------------------------- Sponsor [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- HealthTechMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software